Land: Irland
Språk: engelska
Källa: HPRA (Health Products Regulatory Authority)
DESOGESTREL ETHINYLESTRADIOL
Organon (Ireland) Limited
150/20 Microgram
Tablets
1998-05-30
IRISH MEDICINES BOARD ACTS 1995 AND 2006 MEDICINAL PRODUCTS(CONTROL OF PLACING ON THE MARKET)REGULATIONS,2007 (S.I. NO.540 OF 2007) PA0061/017/001 Case No: 2061885 The Irish Medicines Board in exercise of the powers conferred on it by the above mentioned Regulations hereby grants to ORGANON (IRELAND) LIMITED PO BOX 2857, DRYNAM ROAD, SWORDS, CO. DUBLIN, IRELAND an authorisation, subject to the provisions of the said Regulations, in respect of the product MERCILON 150/20 MICROGRAM TABLETS. The particulars of which are set out in Part I and Part II of the attached Schedule. The authorisation is also subject to the general conditions as may be specified in the said Regulations as listed on the reverse of this document. This authorisation, unless previously revoked, shall continue in force from 07/01/2010. Signed on behalf of the Irish Medicines Board this ________________ A person authorised in that behalf by the said Board. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 07/01/2010_ _CRN 2061885_ _page number: 1_ PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Mercilon 150/20 microgram Tablets. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Desogestrel 150 micrograms Ethinylestradiol 20 micrograms Excipient: also contains 68 mg lactose monohydrate per tablet. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Tablet. The tablets are white, round, biconvex and 6mm in diameter. They are coded on one side “Organon” and an asterix “*” and on the reverse side “TR” above “4”. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Contraception. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Before starting Mercilon, a thorough general m Läs hela dokumentet